Wild-type (senile) amyloidosis natural history, complications and prognosis
Wild-type (senile) amyloidosis Microchapters |
Differentiating Wild-type (senile) amyloidosis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Wild-type (senile) amyloidosis natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis natural history, complications and prognosis |
FDA on Wild-type (senile) amyloidosis natural history, complications and prognosis |
CDC on Wild-type (senile) amyloidosis natural history, complications and prognosis |
Wild-type (senile) amyloidosis natural history, complications and prognosis in the news |
Blogs on Wild-type (senile) amyloidosis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Natural History, Complications, and Prognosis
Natural History
- In amyloidosis, insoluble fibrils of amyloid are deposited in the organs, causing organ dysfunction and eventually death.[1]
- Wild-type (senile) amyloidosis, as the name suggests, is a disease of the elderly.
- The clinical picture of the disease corresponds to the type of organ or organ system involved.
- It most commonly affects the heart and hence, clinical features pertaining to cardiac pathologies, dominate the clinical course of the disease.
- The deposition of transthyretin (TTR) in the heart causes it to start functionally failing.[2]
- The constellation of signs and symptoms of a TTR affected heart can mimic heart failure due to old age, and can thus mask the systemic involvement of wild-type (senile) amyloidosis.
- If left untreated, wild-type (senile) amyloidosis can lead to heart failure with reduced ejection fraction (HFrEF) and eventually death.[3]
Complications
- Wild-type (senile) amyloidosis is most commonly complicated by heart failure with reduced ejection fraction (HFrEF).[3]
- Other complications include:
Prognosis
References
- ↑ Baker KR, Rice L (2012). "The amyloidoses: clinical features, diagnosis and treatment". Methodist Debakey Cardiovasc J. 8 (3): 3–7. PMC 3487569. PMID 23227278.
- ↑ Belinda Ng, Lawreen H. Connors, Ravin Davidoff, Martha Skinner & Rodney H. Falk (2005). "Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis". Archives of internal medicine. 165 (12): 1425–1429. doi:10.1001/archinte.165.12.1425. PMID 15983293. Unknown parameter
|month=
ignored (help) - ↑ 3.0 3.1 Belinda Ng, Lawreen H. Connors, Ravin Davidoff, Martha Skinner & Rodney H. Falk (2005). "Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis". Archives of internal medicine. 165 (12): 1425–1429. doi:10.1001/archinte.165.12.1425. PMID 15983293. Unknown parameter
|month=
ignored (help)